secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orthofix Medical Inc. (OFIX)
CIK:        0000884624
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-263529
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orthofix Q3 pro forma net sales up 5.7%; adj EBITDA margin expands to 12.1%
---------------------------------------------------------------------------

- Pro forma net sales $203.4M, +5.7% constant currency vs Q3 2024; reported net sales $205.6M.
- Non-GAAP adj EBITDA $24.6M (12.1% margin) vs $19.2M (9.8%) prior year; seven consecutive quarters of expansion.
- U.S. Spine Fixation sales +8%, Bone Growth Therapies +6%, Global Orthopedics constant currency +6%.
- FY2025 pro forma net sales guidance narrowed to $810-814M; adj EBITDA guidance raised low end to $84-86M.
- Free cash flow positive $2.5M in Q3; positive FCF expected for full year 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/884624/000119312525263529/0001193125-25-263529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/884624/000119312525263529/ofix-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-263529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer